GO:0045736 negative regulation of cyclin-dependent protein serine/threonine kinase activity: Mechanism, Genes and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:0045736 describes any process that stops, prevents, or reduces the frequency, rate or extent of cyclin-dependent protein serine/threonine kinase activity.
• Cyclin-dependent kinase (CDK) inhibition is a central cell-cycle checkpoint mechanism, and its loss contributes to uncontrolled proliferation in cancer.
• Pharmacological CDK4/6 inhibitors such as palbociclib are approved anticancer agents that mimic endogenous negative regulation of CDK activity.
• Endogenous CDK inhibitors (CKIs) including p21, p27 and p57 are the principal effectors of GO:0045736 in mammalian cells.
• Negative regulation of CDK activity intersects with autophagy, senescence and developmental signaling, as shown by MTORC2-dependent fibroblast senescence and CDK-dependent Sox2 phosphorylation in neurogenesis.
• CRISPR knockout, point-mutation, knock-in and overexpression models enable causal testing of candidate negative regulators of CDK activity.
Description
Cyclin-dependent protein serine/threonine kinases (CDKs) are enzymes that phosphorylate serine or threonine residues on target proteins and drive progression through the cell cycle and transcription. Because unrestrained CDK activity leads to unscheduled proliferation, cells have evolved multiple layers of negative regulation that collectively constitute the Gene Ontology biological process GO:0045736, negative regulation of cyclin-dependent protein serine/threonine kinase activity. This process includes direct binding by CDK inhibitors, post-translational modifications, and upstream signaling that restrains CDK catalytic output. Understanding GO:0045736 is therefore essential for cancer biology, where loss of CDK inhibition is a hallmark of tumorigenesis, and for developmental biology, where timed CDK restraint controls differentiation programs such as neurogenesis. The term also has direct therapeutic relevance because approved CDK4/6 inhibitors such as palbociclib pharmacologically reproduce this negative regulation in breast cancer and other malignancies. In this article we synthesize the QuickGO definition of GO:0045736 with verified PubMed literature to describe its mechanism, key genes, disease links, and the CRISPR-based methods used to study it.
negative regulation of cyclin-dependent protein serine/threonine kinase activity At A Glance
| GO ID | GO:0045736 |
|---|---|
| GO term | negative regulation of cyclin-dependent protein serine/threonine kinase activity |
| Ontology | biological_process |
| Synonym | none |
| Major function | Stops, prevents, or reduces the frequency, rate or extent of CDK serine/threonine kinase activity |
| Effector class | Cyclin-dependent kinase inhibitors (CKIs) such as p21, p27 and p57 |
| Upstream regulators | MTORC2, developmental signaling, and stress-responsive pathways |
| Therapeutic link | CDK4/6 inhibitors such as palbociclib mimic this process in cancer |
| Disease relevance | Cancer, therapy resistance, and senescence-associated pathology |
What Is GO:0045736?
GO:0045736 is a biological process defined by QuickGO as any process that stops, prevents, or reduces the frequency, rate or extent of cyclin-dependent protein serine/threonine kinase activity. In practice, this means any molecular event that lowers the ability of a CDK-cyclin complex to phosphorylate serine or threonine substrates, whether by direct inhibitor binding, sequestration, inhibitory phosphorylation, or degradation of the kinase or its cyclin partner.
Why Is negative regulation of cyclin-dependent protein serine/threonine kinase activity Important in Cell Biology?
Negative regulation of CDK activity is one of the most important brakes on cell division, and its failure is a direct route to oncogenic proliferation. Because CDK4/6 inhibitors such as palbociclib are approved drugs that pharmacologically enforce this process, understanding GO:0045736 informs both target discovery and resistance mechanisms in cancer therapy. The process also shapes non-proliferative outcomes such as fibroblast senescence through MTORC2 signaling and developmental neurogenesis through CDK-dependent Sox2 phosphorylation, making it relevant beyond oncology.
• Provides a cell-intrinsic brake on the G1/S transition by restraining CDK-cyclin complexes.
• Loss of CDK inhibitors such as p21 and p27 is associated with tumor progression and poor prognosis.
• Pharmacological CDK4/6 inhibition with palbociclib clinically validates this process as a drug target.
• Resistance to CDK4/6 inhibitors highlights the need to understand endogenous negative regulation.
• MTORC2-dependent autophagy drives fibroblast senescence, linking CDK restraint to aging biology.
• CDK-dependent Sox2 phosphorylation at serine 39 regulates neurogenesis, showing developmental roles.
• Plant CDK8-AHL10-SUVH2/9 modules show that CDK regulation is conserved in stress responses.
• Phase separation of TAZ can compartmentalize transcription machinery, indirectly influencing CDK-dependent transcription.
• CRISPR screens can identify novel negative regulators of CDK activity for therapeutic targeting.
• Biomarkers of CDK inhibition guide patient selection for CDK4/6 inhibitor therapy.
What Happens During negative regulation of cyclin-dependent protein serine/threonine kinase activity?
Direct inhibition by CDK inhibitors (CKIs)
In simple terms: Special proteins called CKIs stick to CDK-cyclin complexes and block their ability to phosphorylate targets.
The best-characterized mechanism of GO:0045736 is direct binding of cyclin-dependent kinase inhibitors (CKIs) such as p21, p27 and p57 to CDK-cyclin complexes, which sterically prevents substrate phosphorylation and stalls cell-cycle progression. These CKIs are themselves tightly regulated and act as tumor suppressors whose loss removes a key brake on proliferation.
Inhibitory phosphorylation and post-translational control
In simple terms: Adding phosphate groups to CDK itself can switch the kinase off.
Phosphorylation of conserved residues within the CDK ATP-binding pocket by upstream kinases such as Wee1 and Myt1 inhibits catalytic activity, and dephosphorylation by Cdc25 phosphatases reverses this inhibition. This reversible modification provides a rapid switch for negative regulation of CDK activity during checkpoint arrest.
Sequestration and degradation of cyclins
In simple terms: Removing the cyclin partner leaves CDK without its activating subunit.
Because CDK activity requires binding to a regulatory cyclin, processes that sequester or degrade cyclins effectively reduce CDK serine/threonine kinase activity. Ubiquitin-proteasome-mediated cyclin destruction at cell-cycle transitions is a canonical example of negative regulation of CDK activity.
Upstream signaling that restrains CDK activity
In simple terms: External and internal signals can tell CDK to slow down.
Signaling pathways including MTORC2 and stress-responsive modules can indirectly reduce CDK activity; for example, MTORC2-regulated autophagy drives fibroblast senescence, a state associated with reduced proliferative CDK activity. In plants, the CDK8-AHL10-SUVH2/9 module dynamically regulates salt tolerance, illustrating conserved CDK-linked signaling.
Integration with transcription and phase separation
In simple terms: CDK regulation is coupled to how transcription machinery is organized in the nucleus.
Phase separation of TAZ compartmentalizes the transcription machinery to promote gene expression, and such condensates can influence CDK-dependent transcriptional programs. This coupling means negative regulation of CDK activity can also modulate transcription factor phosphorylation, as seen for Sox2 during neurogenesis.
Key Genes Involved in GO:0045736 negative regulation of cyclin-dependent protein serine/threonine kinase activity
The following genes and proteins are established or emerging players in negative regulation of cyclin-dependent protein serine/threonine kinase activity (GO:0045736).
| Gene | Major Role | Research Relevance |
|---|---|---|
| CDKN1A (p21) | CKI that binds and inhibits CDK-cyclin complexes | Tumor suppressor and senescence marker |
| CDKN1B (p27) | CKI that restrains G1/S CDK activity | Prognostic marker in multiple cancers |
| CDKN1C (p57) | CKI important in development | Imprinting and developmental disorders |
| CDKN2A (p16) | CKI that inhibits CDK4/6 | Frequently deleted in cancer |
| CDK4 | Target of negative regulation by p16 and palbociclib | Drug target in breast cancer |
| CDK6 | Target of negative regulation by p16 and CDK4/6 inhibitors | Resistance studies |
| CCND1 (Cyclin D1) | Partner cyclin whose sequestration reduces CDK activity | Amplified in many tumors |
| WEE1 | Kinase that phosphorylates and inhibits CDK1 | Target for checkpoint abrogation |
| CDC25A | Phosphatase that reverses inhibitory phosphorylation | Opposes GO:0045736 |
| MTORC2 | Upstream regulator linked to autophagy and senescence | Senescence and metabolism studies |
| SOX2 | CDK substrate whose phosphorylation regulates neurogenesis | Neural development models |
| TAZ | Phase-separating transcriptional regulator | Condensate and transcription studies |
| CDK8 | Plant CDK involved in salt stress signaling | Stress tolerance research |
| AHL10 | Plant regulator in CDK8 module | Plant stress models |
| SUVH2/9 | Plant chromatin regulators downstream of CDK8 | Epigenetics and stress |
| RB1 | Retinoblastoma protein, downstream of CDK4/6 | CDK4/6 inhibitor response |
| CCNE1 | Cyclin E, partner of CDK2 | Resistance to CDK4/6 inhibition |
How Is negative regulation of cyclin-dependent protein serine/threonine kinase activity Regulated?
Negative regulation of CDK activity is itself regulated at multiple levels. Upstream signaling through MTORC2 can promote autophagy and senescence, indirectly reducing proliferative CDK activity. In plants, the CDK8-AHL10-SUVH2/9 module dynamically regulates salt tolerance, showing that CDK-linked modules respond to environmental stress. Phase separation of TAZ can compartmentalize transcription machinery and thereby influence CDK-dependent transcription. Pharmacological CDK4/6 inhibitors such as palbociclib provide exogenous control of this process, and resistance mechanisms reveal feedback regulation of CDK activity.
negative regulation of cyclin-dependent protein serine/threonine kinase activity and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| CDKN1A (p21) | Cancer, senescence | Knockout and overexpression in cancer cell lines |
| CDKN1B (p27) | Cancer prognosis | Point-mutation knock-in models |
| CDK4 | Breast cancer, CDK4/6 inhibitor response | Knock-in of resistance mutations |
| CDK6 | Therapy resistance | CRISPR knockout in resistant lines |
| SOX2 | Neurodevelopment | Point-mutation knock-in in neural stem cells |
Cancer and CDK inhibitor resistance
Loss of negative regulation of CDK activity is a hallmark of cancer, and CDK4/6 inhibitors such as palbociclib are approved to restore this brake in breast cancer. Resistance to CDK4/6 inhibitors involves multiple mechanisms including RB1 loss and cyclin E overexpression, underscoring the importance of endogenous negative regulation. CDK inhibitors such as p21 and p27 are tumor suppressors whose dysfunction promotes proliferation.
Senescence and aging
MTORC2-regulated autophagy drives fibroblast senescence, a state characterized by reduced proliferative CDK activity and altered negative regulation. This links GO:0045736 to aging biology and age-related pathologies.
Neurodevelopment
CDK-dependent phosphorylation of Sox2 at serine 39 regulates neurogenesis, demonstrating that negative regulation of CDK activity controls neural differentiation. Dysregulation of this process may contribute to neurodevelopmental disorders.
Plant stress and environmental adaptation
The CDK8-AHL10-SUVH2/9 module dynamically regulates salt tolerance in Arabidopsis, showing that CDK regulation is conserved in stress responses and may inform crop engineering.
From negative regulation of cyclin-dependent protein serine/threonine kinase activity-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| Does loss of a CKI increase CDK activity? | CRISPR knockout of CDKN1A or CDKN1B |
| Does a specific phosphorylation site regulate CDK substrate function? | Point-mutation knock-in of SOX2 S39A |
| Can a resistance mutation confer CDK4/6 inhibitor resistance? | Knock-in of RB1 or CCNE1 variants |
| Does overexpression of a negative regulator induce senescence? | Overexpression of CDKN1A or CDKN1B |
| Can a tagged CKI be used to map interactors? | Tagged knock-in of CDKN1B |
| Does MTORC2 regulate CDK activity via autophagy? | Knockout of MTORC2 components |
How to Study the negative regulation of cyclin-dependent protein serine/threonine kinase activity Process
| Method | What It Measures | Typical Application |
|---|---|---|
| CRISPR knockout | Loss-of-function of candidate negative regulators | Identify CKIs controlling CDK activity |
| Point-mutation knock-in | Effect of specific phospho-sites | Test SOX2 S39A in neurogenesis |
| Phosphoproteomics | Global CDK substrate phosphorylation | Quantify CDK inhibition |
| Kinase assay | Direct CDK catalytic activity | Validate CKI function |
| Senescence assay | Senescence-associated beta-galactosidase | Link MTORC2 to CDK inhibition |
| Autophagy flux assay | Autophagic degradation | Study MTORC2-driven senescence |
| CDK4/6 inhibitor resistance assay | Cell viability under palbociclib | Model therapy resistance |
| Phase separation imaging | TAZ condensate formation | Study transcription machinery compartmentalization |
CRISPR knockout and point-mutation screens
CRISPR knockout and point-mutation approaches enable causal testing of candidate negative regulators of CDK activity, such as CDKN1A and CDKN1B. These methods can identify resistance mutations in CDK4/6 inhibitor-treated cells.
Phosphoproteomics and kinase assays
Phosphoproteomics and in vitro kinase assays measure CDK substrate phosphorylation and quantify the impact of negative regulators. Such assays are essential for validating GO:0045736 effectors.
Senescence and autophagy assays
Senescence-associated beta-galactosidase staining and autophagy flux assays link MTORC2 signaling to CDK inhibition and fibroblast senescence.
Developmental and neurogenesis models
Neural stem cell differentiation and Sox2 phosphorylation assays reveal how CDK-dependent phosphorylation regulates neurogenesis.
How CRISPR Can Be Used to Study GO:0045736 negative regulation of cyclin-dependent protein serine/threonine kinase activity
Knockout
CRISPR knockout of CDK inhibitors such as CDKN1A or CDKN1B removes negative regulation of CDK activity, increasing proliferation and providing a model to study GO:0045736 loss.
Point Mutation
Point-mutation knock-in of phosphorylation sites, such as SOX2 S39A, tests whether specific residues mediate CDK-dependent regulation of neurogenesis.
Knock-in
Knock-in of resistance mutations in RB1 or CCNE1 models CDK4/6 inhibitor resistance and reveals how negative regulation is bypassed.
Overexpression
Overexpression of CKIs such as p21 or p27 enforces negative regulation of CDK activity and can induce senescence or cell-cycle arrest.
How EDITGENE Supports negative regulation of cyclin-dependent protein serine/threonine kinase activity Research
Researchers studying negative regulation of cyclin-dependent protein serine/threonine kinase activity-related genes often need to determine whether a candidate gene is causally involved in restraining CDK activity, and CRISPR-based models provide the most direct way to test this.
Contact EDITGENE today to design your custom CRISPR model for negative regulation of cyclin-dependent protein serine/threonine kinase activity research.
Frequently Asked Questions About negative regulation of cyclin-dependent protein serine/threonine kinase activity
What is GO:0045736?
GO:0045736 is the Gene Ontology biological process defined as any process that stops, prevents, or reduces the frequency, rate or extent of cyclin-dependent protein serine/threonine kinase activity.
What genes are involved in negative regulation of CDK activity?
Key genes include CDKN1A (p21), CDKN1B (p27), CDKN1C (p57), CDKN2A (p16), WEE1, and upstream regulators such as MTORC2.
How do CDK inhibitors work?
CDK inhibitors such as p21 and p27 bind to CDK-cyclin complexes and block substrate phosphorylation, thereby enforcing negative regulation of CDK activity.
What diseases are linked to loss of CDK inhibition?
Loss of CDK inhibition is linked to cancer, CDK4/6 inhibitor resistance, and senescence-associated pathologies.
What drugs target CDK activity?
Palbociclib is an approved CDK4/6 inhibitor that pharmacologically mimics negative regulation of CDK activity.
How is negative regulation of CDK activity studied?
CRISPR knockout, point-mutation knock-in, phosphoproteomics, and kinase assays are commonly used.
Does autophagy regulate CDK activity?
MTORC2-regulated autophagy drives fibroblast senescence, which is associated with reduced proliferative CDK activity.
Is CDK regulation conserved in plants?
Yes, the CDK8-AHL10-SUVH2/9 module regulates salt tolerance in Arabidopsis, showing conservation.
What is the role of Sox2 phosphorylation in CDK regulation?
CDK-dependent phosphorylation of Sox2 at serine 39 regulates neurogenesis.
How can CRISPR help study GO:0045736?
CRISPR knockout, point mutation, knock-in, and overexpression models enable causal testing of negative regulators of CDK activity.
Conclusion
GO:0045736, negative regulation of cyclin-dependent protein serine/threonine kinase activity, is a central biological process that restrains CDK-driven proliferation and transcription. Its effectors, including p21, p27, p57 and p16, are critical tumor suppressors, and its pharmacological mimicry by CDK4/6 inhibitors validates it as a therapeutic axis. Beyond cancer, this process intersects with senescence, neurogenesis, and plant stress responses, making it broadly relevant. CRISPR-based knockout, point-mutation, knock-in, and overexpression models, combined with phosphoproteomics and screening, provide robust tools to dissect and target this process.
References
- 1. Bernard M et al.. 2020. Autophagy drives fibroblast senescence through MTORC2 regulation.. Autophagy 16(11):2004-2016 PMID: 31931659
- 2. Guo P et al.. 2025. Salt stress activates the CDK8-AHL10-SUVH2/9 module to dynamically regulate salt tolerance in Arabidopsis.. Nat Commun 16(1):2454 PMID: 40074748
- 3. Lu Y et al.. 2020. Phase separation of TAZ compartmentalizes the transcription machinery to promote gene expression.. Nat Cell Biol 22(4):453-464 PMID: 32203417
- 4. Gomatou G et al.. 2021. Mechanisms of resistance to cyclin-dependent kinase 4/6 inhibitors.. Mol Biol Rep 48(1):915-925 PMID: 33409716
- 5. Dhillon S. 2015. Palbociclib: first global approval.. Drugs 75(5):543-51 PMID: 25792301
- 6. Lim S et al.. 2017. Cyclin-Dependent Kinase-Dependent Phosphorylation of Sox2 at Serine 39 Regulates Neurogenesis.. Mol Cell Biol 37(16) PMID: 28584195
- 7. Harper JW. 1997. Cyclin dependent kinase inhibitors.. Cancer Surv 29:91-107 PMID: 9338098
- 8. Mani S et al.. 2000. Cyclin-dependent kinase inhibitors: novel anticancer agents.. Expert Opin Investig Drugs 9(8):1849-70 PMID: 11060782
